Roivant Sciences (ROIV) FCF Margin (2020 - 2026)
Roivant Sciences' (ROIV) quarterly FCF Margin came in at 10339.36% in Q4 2025, down 721747.0% YoY from N/an in Q4 2024, and up 16.06% on a QoQ basis from 12317.76% in Q3 2025.
Roivant Sciences (ROIV) FCF Margin (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of FCF Margin data on file, last reported at 10339.36% in Q4 2025.
- Quarterly FCF Margin fell 721747.0% year-over-year to 10339.36% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3214.73% (down 125038.0% YoY) and the FY2026 annual result came in at 9173.91%, down 626870.0% from the prior year.
- FCF Margin climbed to 10339.36% in Q4 2025, from 12317.76% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 881.94% in Q3 2021 to a low of 12317.76% in Q3 2025.
- A 5-year average of 4438.09% and a median of 2776.53% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2021 — FCF Margin jumped 521784 bps — and 2025, when it plunged 721747 bps.
- Tracing ROIV's FCF Margin over 5 years: stood at 1175.42% in 2021, then sank by 69 bps to 1992.02% in 2022, then sank by 39 bps to 2776.53% in 2023, then declined by 12 bps to 3121.88% in 2024, then tumbled by 231 bps to 10339.36% in 2025.
- The last three FCF Margin figures came in at 10339.36% (Q4 2025), 12317.76% (Q3 2025), and 9604.52% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Roivant Sciences | 26.52 Bn | 26.52 Bn | 1.16 Mn | -18,629.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18,629.40% |
| Dec 31, 2025 | -10,339.36% |
| Sep 30, 2025 | -12,317.76% |
| Jun 30, 2025 | -9,604.52% |
| Dec 31, 2024 | -3,121.88% |
| Sep 30, 2024 | -5,984.40% |
| Jun 30, 2024 | -2,425.46% |
| Dec 31, 2023 | -2,776.53% |
| Sep 30, 2023 | -5,392.05% |
| Jun 30, 2023 | -1,157.67% |
| Dec 31, 2022 | -1,992.02% |
| Sep 30, 2022 | -1,537.79% |
| Jun 30, 2022 | -6,009.28% |
| Dec 31, 2021 | -1,175.42% |
| Sep 30, 2021 | -881.94% |
| Jun 30, 2021 | -1,855.32% |
| Dec 31, 2020 | -3,146.45% |
| Jun 30, 2020 | -7,073.16% |